First teen test: new obesity drug faces safety trial
NCT ID NCT06536023
Summary
This study tested the safety and how the body processes a new weight-loss medication called IBI362 in Chinese teenagers with obesity. Thirty-six adolescents, aged 12 to 18, who hadn't lost much weight through diet and exercise alone, received either the drug or a placebo. Researchers primarily looked for side effects and also measured changes in weight, body measurements, and blood markers over the course of the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENTS WITH OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Children's Hospital, Capital Medical University Affiliated
Beijin, Beijin, 100045, China
Conditions
Explore the condition pages connected to this study.